Oral components

Abstract

Provided is a composition for the oral cavity in which bitterness is suppressed and the taste is good, and which allows berberine contained in Phellodendron amurense extract to penetrate to the connective tissue layer and exert a preventative or ameliorating effect on periodontal disease.　A composition for the oral cavity that contains (A) 0.02-0.5 mass% of Phellodendron amurense extract as a powder extract, (B) 0.5-3 mass% of sodium alkyl sulfate, and (C) 0.2-2 mass% of polyoxyethylene hydrogenated castor oil having an average number of added mol of ethylene oxide of 3-7 mol, (C) / (A) being 1-20 as a mass ratio and (B) / (C) being 1.2-3.5 as a mass ratio. The composition for the oral cavity also contains (D) 0.01-1 mass% of isopropyl methyl phenol.

Description

[Technical Field]

[0001] The present invention relates to an oral composition in which berberine contained in Phellodendron Bark extract penetrates into the connective tissue layer in the gums, thereby providing the effect of preventing or improving periodontal disease. [Background technology]

[0002] Phellodendron bark extract (an extract of plants from the Rutaceae family, including Phellodendron bark (Phellodendron bark)) containing berberine as an active ingredient is an ingredient with excellent effects in preventing or improving periodontal disease, and when incorporated into oral compositions such as dentifrice compositions, it is expected to have anti-inflammatory and antibacterial effects. Furthermore, berberine contained in Phellodendron bark extract has been reported to have the function of inhibiting osteoclast formation (osteoclast differentiation inhibitory effect) by acting on macrophages (Non-Patent Document 1). Therefore, it was expected that this function would prevent the destruction of alveolar bone due to excessive osteoclast formation caused by inflammation associated with periodontal disease, thereby more effectively preventing or improving periodontal disease. However, it was technically difficult to penetrate berberine into the gingival connective tissue layer, where macrophages reside in the gingival epithelium, in oral compositions, and the above function could not be satisfactorily expressed.

[0003] It is known that the stability of berberine can be improved by adding polyoxyethylene hydrogenated castor oil, a nonionic surfactant, to a berberine-containing oral composition. Patent Document 1 (JP 8-175941 A) discloses that a toothpaste composition containing polyoxyethylene hydrogenated castor oil with an average ethylene oxide addition mole number of 20 or more retains a high percentage of berberine even after storage at 50°C for three months. Patent Documents 2 to 4 (JP 2012-92042 A, JP 2012-158559 A, JP 2011-132137 A) also use polyoxyethylene hydrogenated castor oil to improve the storage stability of berberine added to a dentifrice composition. Patent Document 5 (JP 2005-187329 A) proposes that the combination of berberine with condensed phosphate and polyoxyethylene hydrogenated castor oil can reduce irritation and improve the storage stability of berberine. However, neither document focuses on the permeability of berberine into gingival tissue, and conventional techniques have not been able to increase the permeability of berberine into gingival tissue and allow it to reach and penetrate into the connective tissue layer. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] Japanese Patent Application Publication No. 8-175941 [Patent Document 2] Japanese Patent Application Laid-Open No. 2012-92042 [Patent Document 3] Japanese Patent Application Laid-Open No. 2012-158559 [Patent Document 4] Japanese Patent Application Laid-Open No. 2011-132137 [Patent Document 5] Japanese Patent Application Laid-Open No. 2005-187329 [Non-patent literature]

[0005] [Non-Patent Document 1] European Journal of Pharmacology 580(2008), p70-79 Summary of the Invention [Problem to be solved by the invention]

[0006] The present invention has been made in view of the above circumstances, and aims to provide an oral composition that allows the berberine contained in Phellodendron Bark extract to reach and penetrate into the connective tissue layer in the gums, thereby effectively preventing or improving periodontal disease. [Means for solving the problem]

[0007] As a result of intensive research conducted by the present inventors to achieve the above-mentioned object, they have found that when an oral composition containing a specific amount of Phellodendron bark extract is combined with a specific amount and ratio of a specific anionic surfactant and a specific nonionic surfactant, the permeability of the berberine contained in the Phellodendron bark extract into gingival tissue is increased, allowing the berberine to reach and penetrate the connective tissue layer within the gingival epithelium, and also suppressing the bitterness inherent in the Phellodendron bark extract, ensuring a pleasant taste when used. That is, the present inventors have found that by blending (A) 0.02 to 0.5 mass% of Phellodendron Bark extract, (B) 0.5 to 3 mass% of sodium alkyl sulfate, and (C) 0.2 to 2 mass% of polyoxyethylene hydrogenated castor oil having an average added mole number of ethylene oxide of 3 to 7, with a mass ratio of (C) / (A) of 1 to 20 and a mass ratio of (B) / (C) of 1.2 to 3.5, it is possible to provide an oral composition that enhances the permeability of berberine contained in component (A) into gingival tissue, penetrates into the connective tissue layer within the gingiva, and effectively prevents or improves periodontal disease while also tasting good, thereby achieving the present invention.

[0008] In more detail, the present inventors conducted a study focusing on anionic surfactants, which are believed to contribute to the penetration of water-soluble active ingredients. By adding (B) sodium alkyl sulfate, one of the anionic surfactants, to an oral composition containing (A) Phellodendron Bark extract, the penetration of berberine contained in component (A) into gingival tissues could be improved to some extent. However, the use of component (B) in combination amplified the unique bitterness of component (A), worsening the taste and making the composition unsuitable for use. Furthermore, when a nonionic surfactant was inappropriately added to mask the unique bitterness, the function of component (B) on berberine was inactivated, and the penetration of berberine into gingival tissues was no longer improved. However, when a specific polyoxyethylene hydrogenated castor oil (C), a nonionic surfactant, is used in combination with component (B), components (B) and (C) interact with each other when the amount of each component is within a specific range and the mass ratios of (C) / (A) and (B) / (C) are within their respective specific ranges. As a result, the combination of the specific surfactants suppresses the unique bitterness of component (A) without amplifying it, maintaining a pleasant taste, and allowing the berberine contained in component (A) to reach and penetrate the connective tissue layer within the gingival epithelium. Therefore, the oral composition of the present invention not only has the anti-inflammatory and antibacterial effects of berberine contained in component (A), but also prevents bone destruction caused by abnormal activation of osteoclasts through the function of berberine acting on macrophages in the gingival connective tissue layer to inhibit osteoclast formation (osteoclast differentiation inhibitory effect), thereby providing more effective prevention or inhibition of periodontal disease. As shown in the Examples below, in oral compositions of the present invention containing specific amounts of components (A), (B), and (C) and having the mass ratios (C) / (A) and (B) / (C) within specific ranges, berberine reached and penetrated into the gingival connective tissue layer, exhibiting excellent reachability of berberine to the gingival connective tissue (degree of reach and penetration into the gingival connective tissue layer) and a good feel in use (absence of bitterness). In contrast, as shown in the Comparative Examples below, when the mass ratio of (C) / (A) or the mass ratio of (B) / (C) was inappropriate, the reachability of berberine to the gingival connective tissue or the feel in use (absence of bitterness) was poor (Comparative Examples 2 to 4, 7, 9, and 10). In particular, in Comparative Examples 3 and 9, where the mass ratio of (B) / (C) was too small, berberine was poorly able to reach the gingival connective tissue and did not penetrate into the connective tissue layer. Furthermore, when the anionic surfactant sodium lauroyl methyl taurate was used instead of component (B), berberine was less able to reach the gingival connective tissue (Comparative Example 11), and when polyoxyethylene hydrogenated castor oil with an average number of ethylene oxide added exceeding 7 was used instead of component (C), berberine was less able to reach the gingival connective tissue (Comparative Examples 5, 6, and 8).

[0009] Therefore, the present invention provides the following oral compositions. [1] (A) Phellodendron bark extract in a powder extract amount of 0.02 to 0.5% by mass, (B) 0.5 to 3 mass% of sodium alkyl sulfate and (C) 0.2 to 2 mass% of polyoxyethylene hydrogenated castor oil having an average added mole number of ethylene oxide of 3 to 7 moles wherein the mass ratio of (C) / (A) is 1 to 20 and the mass ratio of (B) / (C) is 1.2 to 3.5. [2] (A) The oral composition according to [1], wherein the phellodendron bark extract has a berberine content of 3% by mass or more in the powder extract. [3] The oral composition according to [1] or [2] further contains (D) 0.01 to 1% by mass of isopropylmethylphenol. [4] The oral composition according to any one of [1] to [3], which is a dentifrice composition. [Effects of the Invention]

[0010] According to the present invention, an oral composition can be provided in which the permeability of berberine contained in component (A) into gingival tissue is enhanced, allowing it to reach and penetrate into the connective tissue layer within the gingiva, effectively preventing or ameliorating periodontal disease, and also having a pleasant taste due to its reduced bitterness.The oral composition of the present invention is effective for preventing or ameliorating periodontal disease because, in addition to the anti-inflammatory and antibacterial effects of berberine, it can also prevent bone destruction due to abnormal activation of osteoclasts by inhibiting osteoclast differentiation. DETAILED DESCRIPTION OF THE INVENTION

[0011] The present invention will be described in further detail below. The oral composition of the present invention contains (A) Phellodendron Bark extract, (B) sodium alkyl sulfate, and (C) polyoxyethylene hydrogenated castor oil having an average number of added moles of ethylene oxide of 3 to 7, each in a specific amount, and the mass ratios of (C) / (A) and (B) / (C) are each within a specific range.

[0012] (A) Phellodendron bark extract contains berberine as an active ingredient, which has anti-inflammatory and antibacterial effects, and furthermore, by acting on macrophages, it also inhibits osteoclast differentiation, thereby providing the effect of preventing or suppressing periodontal disease. The Phellodendron bark extract is a solvent extract of plants of the Rutaceae family, including Phellodendron bark (Phellodendron bark), and one obtained by a known method can be used. The Phellodendron Bark extract may be in a liquid form, a dried solid form, or a powdered extract may be used. Specifically, the raw material may be bark of a citrus plant such as Phellodendron amurense. The extraction solvent can be a hydrophilic solvent, such as water, lower monohydric alcohols such as ethanol and propanol, and polyhydric alcohols such as 1,3-butylene glycol and propylene glycol. One or more of these solvents can be used alone or in combination. Conventional extraction conditions and post-treatment methods can be used. Phellodendron bark extract that is listed in the quasi-drug raw material standards, Phellodendron bark powder that is listed in the pharmaceutical additive standards, or commercially available products can be used. However, in terms of the effectiveness of the present invention, it is particularly preferred that the berberine content in the powder extract is 3% (mass %, the same applies below) or more, more preferably 5% or more, and especially 5 to 7%. Specific examples of commercially available products of such Phellodendron bark extract include a powder extract obtained by hot water extraction of Phellodendron bark and spray drying, manufactured by Ogi Pharmaceutical Co., Ltd., under the trade name Phellodendron Bark Extract, and a liquid extract containing ethanol, manufactured by Maruzen Pharmaceutical Co., Ltd., under the trade name Phellodendron Bark Extract-J.

[0013] The amount of (A) Phellodendron Bark Extract, as powdered extract, is 0.02 to 0.5% of the total composition, with 0.02 to 0.2% being particularly preferred. If the amount of (A) ingredient is less than 0.02%, the berberine will not reach the gingival connective tissue as easily, and if it is more than 0.5%, the bitterness of the ingredient itself will be too strong and the taste will be unpleasant. Furthermore, the amount of (A) Phellodendron Bark Extract is preferably 0.001 to 0.025% of the total composition in terms of berberine, more preferably 0.0025 to 0.01%. Within this range, berberine can be sufficiently delivered to the gingival connective tissue, and bitterness can be sufficiently suppressed.

[0014] (B) Sodium alkyl sulfate promotes the penetration of berberine contained in component (A) into gingival tissue, and has the effect of allowing berberine to reach and penetrate into the gingival connective tissue layer. (B) Sodium alkyl sulfate is preferably one in which the carbon chain length of the alkyl group is 8 to 18, particularly 10 to 16, and examples thereof include sodium lauryl sulfate and sodium myristyl sulfate. Commercially available products such as those manufactured by BASF Japan Ltd. can be used. The amount of (B) sodium alkyl sulfate is 0.5 to 3% of the total composition, preferably 0.7 to 2%. If the amount is less than 0.5%, the delivery of berberine to the gingival connective tissue is poor, and if it exceeds 3%, the bitterness derived from component (A) is amplified and cannot be suppressed, resulting in an unpleasant taste.

[0015] (C) Polyoxyethylene hydrogenated castor oil with an average number of added moles of ethylene oxide of 3 to 7 moles, when used in combination with component (B), maintains the ability of component (B) to reach and penetrate into the connective tissue layer without interfering with the penetration-promoting effect of component (B) of the berberine contained in component (A) into the gingival junction, and also suppresses the bitterness derived from component (A). The average number of moles of ethylene oxide added in polyoxyethylene hydrogenated castor oil is 3 to 7 moles. If the number exceeds 7 moles, the above-mentioned effect of component (B) on berberine is inhibited and the oil has poor accessibility to gingival connective tissue. Therefore, oils with less than 3 moles are not generally commercially available. Such polyoxyethylene hydrogenated castor oil may be commercially available from Nippon Emulsion Co., Ltd., Aoki Oil & Fat Industries Co., Ltd., and the like.

[0016] The amount of component (C) in the composition is 0.2 to 2%, preferably 0.3 to 1.5%, of the total composition. If the amount is less than 0.2%, the bitterness from component (A) is not suppressed, resulting in an unpleasant taste. If the amount is more than 2%, the delivery of berberine to the gingival connective tissue is impaired.

[0017] In the present invention, the ratio (C) / (A) of the component (A) (the amount of component (A) blended as a powder extract) to the amount of component (C) blended is a mass ratio of 1 to 20, preferably 5 to 15. If the mass ratio of (C) / (A) is less than 1, the bitterness derived from component (A) is not suppressed, resulting in an unpleasant taste, while if it exceeds 20, the effect of promoting berberine penetration into gingival tissues is reduced, resulting in poor accessibility to gingival connective tissues.

[0018] Furthermore, the ratio (B) / (C) of the amounts of component (B) and component (C) is 1.2 to 3.5 by mass, preferably 2.0 to 3.5. If the mass ratio (B) / (C) is less than 1.2, the effect of promoting berberine penetration into gingival tissue is low, and its reach to gingival connective tissue is poor. If the mass ratio (B) / (C) is more than 3.5, the bitterness derived from component (A) is not suppressed, resulting in an unpleasant taste.

[0019] The oral composition of the present invention preferably further contains (D) isopropylmethylphenol (3-methyl-4-isopropylphenol). The incorporation of component (D) in addition to components (B) and (C) enhances the gingival tissue penetration-promoting effect of berberine contained in component (A), resulting in better reach to gingival connective tissue. As isopropylmethylphenol, commercially available products such as those manufactured by Osaka Kasei Co., Ltd. can be used. The amount of (D) isopropylmethylphenol is preferably 0.01 to 1% of the total composition, more preferably 0.05 to 0.5%. The higher the amount, the more berberine reaches the gingival connective tissue, but in order to ensure solubility, it is preferably 1% or less.

[0020] The oral composition of the present invention is preferably prepared as a dentifrice composition such as toothpaste or liquid toothpaste, and particularly as a toothpaste. In addition to the above-mentioned components, other known components can be blended as needed within a range that does not impair the effects of the present invention. For example, toothpaste can contain abrasives, thickeners, binders, surfactants, and, if necessary, sweeteners, colorants, preservatives, flavorings, and active ingredients. These components can be blended in normal amounts within a range that does not impair the effects of the present invention, and the blending amounts shown below are all based on the total amount of the composition.

[0021] Examples of abrasives include silica-based abrasives such as silicic anhydride, precipitated silica, aluminosilicate, and zirconosilicate, calcium phosphate compounds, calcium carbonate, and synthetic resin-based abrasives. The amount of abrasive blended is usually 2 to 50%, and particularly 10 to 40%.

[0022] Examples of the thickening agent include sugar alcohols such as sorbitol and xylitol, and polyhydric alcohols such as glycerin and propylene glycol. The amount of thickening agent blended is usually 5 to 50%, particularly 10 to 30%.

[0023] The binder may be organic or inorganic. Specific examples include organic binders such as cellulose derivatives (e.g., sodium carboxymethylcellulose, methylcellulose, hydroxymethylcellulose), alginic acid derivatives, gums (e.g., xanthan gum), and carrageenan, and inorganic binders (e.g., thickening anhydrous silicic acid, thickening aluminum silica). The binder content is typically 0.1 to 10%, and particularly 0.2 to 5%.

[0024] As an optional surfactant, surfactants other than components (B) and (C), such as amphoteric surfactants and cationic surfactants, can be blended within the range that does not impair the effects of the present invention. The blending amount is preferably 0 to 10%, particularly 0.001 to 5%, and these optional surfactants may not be blended.

[0025] Sweeteners include sodium saccharin. Coloring agents include Blue No. 1, Yellow No. 4, titanium dioxide, and the like. Examples of the preservative include parahydroxybenzoic acid esters, benzoic acid and salts thereof.

[0026] Fragrances include peppermint oil, spearmint oil, anise oil, eucalyptus oil, wintergreen oil, cassia oil, clove oil, thyme oil, sage oil, lemon oil, orange oil, peppermint oil, cardamom oil, coriander oil, mandarin oil, lime oil, lavender oil, rosemary oil, laurel oil, chamomile oil, caraway oil, marjoram oil, bay oil, lemongrass oil, origanum oil, pine needle oil, neroli oil, rose oil, jasmine oil, grapefruit oil, and sweet Natural fragrances such as citrus fruit oil, yuzu oil, iris concrete, peppermint absolute, rose absolute, orange flower, and processed fragrances (front distillation, tail distillation, liquid-liquid extraction, essence, powder fragrance, etc.) of these natural fragrances, as well as menthol, carvone, anethole, cineole, methyl salicylate, cinnamic aldehyde, eugenol, 3-l-menthoxypropane-1,2-diol, thymol, linalool, linalyl acetonitrile ... It is also possible to use in combination with known flavoring materials used in oral compositions, such as single flavorings such as methyl methacrylate, limonene, menthone, menthyl acetate, N-substituted-paramenthan-3-carboxamide, pinene, octyl aldehyde, citral, pulegone, carbeyl acetate, anisaldehyde, ethyl acetate, ethyl butyrate, allyl cyclohexane propionate, methyl anthranilate, ethyl methylphenylglycidate, vanillin, undecalactone, hexanal, butanol, isoamyl alcohol, hexenol, dimethyl sulfide, cyclotene, furfural, trimethylpyrazine, ethyl lactate, and ethyl thioacetate, as well as compound flavorings such as strawberry flavor, apple flavor, banana flavor, pineapple flavor, grape flavor, mango flavor, butter flavor, milk flavor, fruit mix flavor, and tropical fruit flavor. The amount of fragrance to be added is not particularly limited, but the above fragrance materials are preferably used in an amount of 0.000001 to 1% in the composition, and fragrances using the above fragrance materials are preferably used in an amount of 0.1 to 2% in the composition.

[0027] Optional active ingredients include cationic disinfectants such as cetylpyridinium chloride, anti-inflammatory agents such as tranexamic acid and allantoin, enzymes such as dextranase, fluorine-containing compounds such as sodium fluoride and sodium monofluorophosphate, water-soluble phosphate compounds, inorganic salts such as sodium chloride, potassium nitrate and aluminum lactate, vitamins such as ascorbic acid and tocopherol acetate, anti-tartar agents, anti-plaque agents, etc. These active ingredients can be blended in effective amounts within a range that does not interfere with the effects of the present invention. [Example]

[0028] The present invention will be described in detail below with reference to examples and comparative examples, but the present invention is not limited to the following examples. In the following examples, % indicates % by mass unless otherwise specified.

[0029] [Examples and Comparative Examples] Dentifrice compositions (toothpastes) having the compositions shown in Tables 1 to 4 were prepared by conventional methods and evaluated by the following methods, with the results also shown in the tables. Examples 2, 3, 4, 6, 7, and 9 to 13 are reference examples.

[0030] (1) Berberine's ability to reach gingival connective tissue A pig mandible for meat (Shibaura Organ Co., Ltd., Tokyo) was immersed in a solution prepared by diluting 80 g of the dentifrice composition three times with artificial saliva and allowed to stand at 37°C. After 6 hours, the pig mandible was removed and thoroughly washed with purified water. The gingiva was excised using a biopsy trephine (8 mm), and the epithelium and connective tissue were peeled off. After measuring the mass of the connective tissue, it was shredded with a scalpel, and berberine was extracted by adding 0.5 mL of methanol. Berberine was quantified by high-performance liquid chromatography (HPLC) and the amount of berberine per mass of connective tissue (μg / g, berberine amount per unit tissue) was calculated. The equipment used and test conditions are as follows: (Equipment used) Pump: Shimadzu Corporation LC-20AD Sample introduction unit: Shimadzu Corporation SIL-20AC Detector: Shimadzu Corporation SPD-20A Column thermostat: Shimadzu Corporation CTO-20AC ·Eluent flow rate: 1mL / min (Test conditions) Detector: UV spectrophotometer (measurement wavelength: 273 nm) Column: COSMOSIL 5C 18 -MS-II Column temperature: 40℃ Mobile phase: 5 g of sodium lauryl sulfate and 3 g of L-tartaric acid were dissolved in 400 mL of water, and 400 mL of acetonitrile and 200 mL of methanol were added.

[0031] The amount of berberine per mass of connective tissue (μg / g) obtained was used to evaluate the reachability of berberine to the gingival connective tissue (degree of penetration of berberine into the gingival connective tissue layer) according to the following criteria: A score of 2 or more was considered to indicate that berberine had reached and penetrated into the gingival connective tissue, and the reachability to the gingival connective tissue was deemed acceptable. Grading criteria 4 points: Berberine content is 0.3μg / g or more 3 points: Berberine content is 0.2μg / g or more but less than 0.3μg / g 2 points: A berberine peak was detected, and the amount of berberine was 0.2 μg / g. less than 1 point: No berberine peak detected

[0032] (2) Usability (lack of bitterness) Nine subject monitors squeezed out 1 g of a dentifrice composition packed in a standard laminated tube container, placed it on a toothbrush, and brushed their teeth for 3 minutes. The taste (bitterness) was judged according to the following rating scale. The average of the nine evaluation scores was calculated, and the usability (absence of bitterness) was evaluated according to the following rating scale. Products with a rating of ◯ or ⊚ were judged to have a good taste with reduced bitterness and to have an acceptable usability. Grading criteria 4 points: No bitter taste in the mouth 3 points: Almost no bitterness in the mouth 2 points: A slightly bitter taste is felt in the mouth, but at an acceptable level 1 point: Very bitter taste in the mouth Evaluation criteria ◎: Average score is between 3.0 and 4.0 points 〇: Average score is 2.0 or more and less than 3.0 points ×: Average score is less than 2.0 points

[0033] Details of the raw materials used are shown below. (A) Phellodendron Bark Extract: Ogi Pharmaceutical Co., Ltd., product name: Phellodendron Bark Extract (dried powder extract) In this experiment, we used Phellodendron bark extract, which contains 5% berberine in powder extract. A sachet was used. (B) Sodium lauryl sulfate: BASF Japan Ltd., product name: Texapon OC-P Sodium lauroyl methyl taurate (comparison product): Nikko Chemicals Co., Ltd., product name: NIKKOL LMT (C) Polyoxyethylene (5) hydrogenated castor oil: Manufactured by Nippon Emulsion Co., Ltd., product name: EMALEX HC-5 Average number of moles of ethylene oxide added: 5 (C) Polyoxyethylene (3) hydrogenated castor oil; Aoki Oil & Fat Industries Co., Ltd., product name: CW-3 Average number of moles of ethylene oxide added: 3 (C) Polyoxyethylene (7) Hydrogenated Castor Oil: Manufactured by Nippon Emulsion Co., Ltd., product name: EMALEX HC-7 Average number of moles of ethylene oxide added: 7 Polyoxyethylene (10) hydrogenated castor oil (comparison product): Manufactured by Nippon Emulsion Co., Ltd., product name: EMALEX HC-10 Average number of moles of ethylene oxide added: 10 Polyoxyethylene (20) hydrogenated castor oil (comparison product): Manufactured by Nippon Emulsion Co., Ltd., product name: EMALEX HC-20 Average number of moles of ethylene oxide added: 20 (D) Isopropylmethylphenol: Osaka Kasei Co., Ltd., product name: isopropyl methylphenol

[0034] [Table 1]

[0035] [Table 2]

[0036] [Table 3]

[0037] [Table 4]

Claims

1. (A) Phellodendron bark extract having a berberine content of 3% by mass or more in the powder extract, in an amount of 0.02 to 0.5% by mass as a powder extract of the entire oral composition, and the berberine content contained in the Phellodendron bark extract is 0.001 to 0.025% by mass as a whole oral composition; (B) 0.7 to 2% by mass of sodium alkyl sulfate and (C) 0.2 to 2 mass% of polyoxyethylene hydrogenated castor oil having an average added mole number of ethylene oxide of 3 to 7 moles The oral composition comprises: (C) / (A) in a mass ratio of 5 to 15; and (B) / (C) in a mass ratio of 1.2 to 3.

5.

2. 2. The oral composition according to claim 1, wherein the berberine content is 0.0025 to 0.01% by mass of the entire oral composition.

3. The oral composition according to claim 1 or 2, further comprising (D) 0.01 to 1% by mass of isopropylmethylphenol.

4. The oral composition according to any one of claims 1 to 3, which is a dentifrice composition.

Images